Dana-Farber Cancer Institute

About the Dana-Farber Beth Israel Deaconess Cancer Collaboration

    In this section

    Short placeholder heading

    omar-nadeem-and-clinical-staff-600x368.jpg

    The new clinical collaboration between Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center (BIDMC) will give patients the best of both worlds — dedicated cancer care led by Dana-Farber clinicians and immediate access to the surgical and other non-cancer specialties of BIDMC and its affiliated faculty physicians.

    Every day, Dana-Farber clinicians and researchers discover important new approaches to prevent, treat, and cure cancer. This new collaboration ensures that our inpatient facilities and clinical collaborations will be designed and positioned for the future of cancer care.

    Like Dana-Farber, BIDMC is a world-class, Harvard-affiliated teaching hospital, with Harvard faculty physicians. It shares our vision to create a forward-looking model of cancer care that further advances the patient and caregiver experience, expands access to value-driven care, and fosters scientific discovery. Their shared vision and legacy of excellence make them a terrific collaboration partner for us.

    Our world-leading discoveries will best serve patients in a state-of-the-art hospital, equipped to adapt to rapidly changing technology and designed solely to support cancer patients. With our plans for a new adult inpatient cancer hospital, we will be able to manage all aspects of cancer care for our patients and their loved ones in the Longwood Medical area. 

    fch-rendering-4-600x412.jpg

    Building the Future of Cancer Care

    Our proposed Future Cancer Hospital will seamlessly connect inpatient, outpatient, and research services, advancing Dana-Farber's bench-to-bedside oncology model. Learn more about the building design and location, and follow the latest updates on our progress.

    About Our Proposed Future Cancer Hospital